A Phase 1 interventional study of MK-1942 and Donepezil in Alzheimer's Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 4 sites in United States. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-08-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.
Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 47th largest by enrollment of the 58 interventional ones that give a count, is one of 2 that started in 2021, is one of 20 in phase 1, and was the 56th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 50+
Eisai Inc.
Ages 50–85
By country, each count listing its studies:
Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 79 across the 58 interventional studies. Of the 56 that completed or were terminated, 21 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
31 studies in Alzheimer Disease by Merck & Co., Inc: 1 open now, 1 under way, none of them phase 3. Of 29 finished, 20 (69%) have results posted.
Among the 31 studies in Alzheimer Disease by Merck & Co., Inc, this one is the 19th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2021, is one of 18 in phase 1, and was the 23rd registered.
Merck & Co., Inc’s Alzheimer Disease studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing donepezil in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 31 in Alzheimer Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study investigated the effects on safety and pharmacokinetics (PK) of MK-1942 and donepezil when co-administered to participants with Alzheimer's Disease with mild-to-moderate cognitive impairment stably treated with donepezil. The objectives of this study were to determine if the combination of MK-1942 with donepezil increases the incidence or severity of adverse events (AEs) previously reported for these agents alone, or results in unanticipated AEs in the patient population targeted for MK-1942 treatment. In addition, changes in the PK parameters of either MK-1942 or donepezil as a result of co-administration were assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive Dose Level 1: 8-mg MK-1942 twice daily (BID) x 7 days (7D), Day 1 to Day 7; Dose Level 2: 15-mg MK-1942 BID x 7D, Day 8 to Day 14; Dose Level 3: 30-mg MK-1942 BID x 7D, Day 15 to Day 21; Dose Level 4: ≤50-mg MK-1942 BID x 7D (Provisional Dose Level), Day 22 to Day 28 All participants to receive Donepezil once daily.
Drug: MK-1942 · Drug: Donepezil
Placebo to MK-1942 BID x 21 \[28\] D All participants to receive Donepezil once daily.
Drug: Donepezil · Drug: Placebo
Number of Participants With ≥1 Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to Day 42
Number of Participants Discontinuing From Study Therapy Due to an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to Day 28
Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) Findings
The number of participants with clinically significant 12-lead ECGs is presented. Recordings were made throughout the study, with the participant in a semi-recumbent position having rested in this position for at least 10 minutes beforehand.
Time frame: Up to Day 28
Number of Participants With Abnormal (Impaired) Results on Targeted Neurological Exams
The number of participants with abnormal (impaired) results on targeted neurological exams will be presented. The targeted neurological exam contains Modules 1, 2 and 5 of the general examination, focusing on arousal, cranial nerve function, and gait and will be administered several times throughout the treatment period starting on Day 1 up until Day 29. The number of participants with abnormal (impaired) results on targeted neurological exams will be reported. Each exam will be graded as Normal or Impaired with the abnormality described.
Time frame: Up to 29 days
Number of Participants Who Reported Suicidal Ideation and/or Behavior on Study Based on Responses to the Columbia Suicide Severity Rating Scale (C-SSRS)
The number of participants with suicidality using the C-SSRS is presented. The C-SSR will be used in this study only for the purpose of safety monitoring by measuring the incidence of different types of suicidality categories during treatment. C-SSRS assessment will be based upon a clinician's interpretation of the participant's responses to the C-SSRS questions, not by a numbered scale. Suicidal ideation and/or behaviors identified on the C-SSRS may not be considered an adverse event, based on the investigator's judgment. Participants who report at least one occurrence of suicidal behavior or suicidal ideation will be counted as having experienced suicidality. Suicidal behavior includes suicide attempt, aborted attempt, interrupted attempt, or preparatory behavior. Suicidal ideation include a wish to die or active suicidal thought with or without method, intent or plan.
Time frame: Up to 42 days
Change From Baseline in Heart Rate (HR)
The mean change from baseline in HR is presented. Change in HR was determined the first day of treatment with a new dose of MK-1942. A negative value indicates a decrease in HR relative to baseline, and a positive value indicates an increase.
Time frame: Baseline (Day -1) and Days 1, 8, 15, and 22: 2 hours postdose
Change From Baseline in Systolic Blood Pressure (SBP)
The mean change from baseline in SBP is presented. Change in SBP was determined the first day of treatment with a new dose of MK-1942. Negative values represent a decrease in SBP relative to baseline, and positive values represent an increase.
Time frame: Baseline (Day -1) and Days 1, 8, 15, and 22: 2 hours postdose
Mean Change From Baseline in Diastolic Blood Pressure (DBP)
The mean change from baseline in DBP is presented. Change in DBP was determined the first day of treatment with a new dose of MK-1942. Negative values represent a decrease in DBP relative to baseline, and positive values represent an increase.
Time frame: Baseline (Day -1) and Days 1, 8, 15, and 22: 2 hours postdose
Number of Participants With Abnormal Clinical Chemistry Test Results Reported as Adverse Events
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with abnormal chemistry-related AEs is reported.
Time frame: Up to 42 days
Number of Participants With Abnormal Clinical Hematology Test Results Reported as Adverse Events
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with abnormal hematology-related AEs is reported.
Time frame: Up to 42 days
Number of Participants With Abnormal Urinalysis Results Reported as Adverse Events
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with an abnormal urinalysis results AE is reported.
Time frame: Up to 42 days
Area Under the Plasma Concentration-Time Curve (AUC) From Dosing to 12 Hours Postdose (AUC0-12) of MK-1942
AUC0-12 is reported for the first day of treatment of each MK-1942 dose.
Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
AUC From Dosing to 24 Hours Postdose (AUC0-24) of MK-1942
AUC0-24 is reported for the first day of treatment of each MK-1942 dose. Due to twice daily dosing, AUC0-24 was calculated as "AUC0-24 = AUC0-12 x 2".
Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Maximum Plasma Concentration (Cmax) of MK-1942
Cmax is reported for the first day of treatment of each MK-1942 dose.
Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Trough Plasma Concentration (Ctrough) of MK-1942
Ctrough is reported for the first day of treatment of each MK-1942 dose. Data from healthy elderly participants used for statistical analyses are unpublished findings from study MK-1942-004.
Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Time to Reach Maximum Plasma Concentration (Tmax) of MK-1942
Tmax is reported for the first day of treatment of each MK-1942 dose.
Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Apparent Terminal Plasma Half-Life (t½) of MK-1942
t½ is reported for MK-1942 50 mg.
Time frame: Day 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Apparent Clearance at Steady-state (CLss/F) of MK-1942
CLss/F is reported for MK-1942 50 mg.
Time frame: Day 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Apparent Volume of Distribution at Steady State (Vzss/F) of MK-1942
Vzss/F is reported for MK-1942 50 mg.
Time frame: Day 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
AUC0-24 of Donepezil
AUC0-24 is reported for donepezil 10 mg alone (Day -1) or with MK-1942 50 mg (Day 28). Due to twice daily dosing, AUC0-24 was calculated as "AUC0-12 x 2".
Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Cmax of Donepezil
Cmax is reported for donepezil 10 mg alone (Day -1) or with MK-1942 50 mg (Day 28).
Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Ctrough of Donepezil
Ctrough is reported for donepezil 10 mg alone (Day -1) or with MK-1942 50 mg (Day 28).
Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Tmax of Donepezil
Tmax is reported for donepezil 10 mg alone (Day -1) or with MK-1942 50 mg (Day 28).
Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Male and female adult (≥50 to ≤85 years of age) participants with Alzheimer's disease (AD) and mild-to-moderate cognitive impairment were enrolled at 4 study centers in the United States.
| Milestone | MK-1942 AD | Placebo + Donepezil AD |
|---|---|---|
| Started | 22 | 5 |
| Completed | 17 | 5 |
| Not completed | 5 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | MK-1942 8 mg + Donepezil AD | MK-1942 15 mg + Donepezil AD | MK-1942 30 mg + Donepezil AD | MK-1942 50 mg + Donepezil AD | Placebo + Donepezil AD |
|---|---|---|---|---|---|
| Number of Participants With ≥1 Adverse Event (AE) | 13 | 4 | 4 | 5 | 4 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | MK-1942 8 mg AD | MK-1942 15 mg AD | MK-1942 30 mg AD | MK-1942 50 mg AD | Placebo AD |
|---|---|---|---|---|---|
| Number of Participants Discontinuing From Study Therapy Due to an Adverse Event (AE) | 0 | 0 | 0 | 0 | 0 |
The number of participants with clinically significant 12-lead ECGs is presented. Recordings were made throughout the study, with the participant in a semi-recumbent position having rested in this position for at least 10 minutes beforehand.
| Participants | MK-1942 8 mg | MK-1942 15 mg | MK-1942 30 mg | MK-1942 50 mg | Placebo AD |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) Findings | 1 | 0 | 0 | 0 | 1 |
The number of participants with abnormal (impaired) results on targeted neurological exams will be presented. The targeted neurological exam contains Modules 1, 2 and 5 of the general examination, focusing on arousal, cranial nerve function, and gait and will be administered several times throughout the treatment period starting on Day 1 up until Day 29. The number of participants with abnormal (impaired) results on targeted neurological exams will be reported. Each exam will be graded as Normal or Impaired with the abnormality described.
| Participants | MK-1942 8 mg | MK-1942 15 mg | MK-1942 30 mg | MK-1942 50 mg | Placebo AD |
|---|---|---|---|---|---|
| Number of Participants With Abnormal (Impaired) Results on Targeted Neurological Exams | 0 | 0 | 0 | 0 | 0 |
The number of participants with suicidality using the C-SSRS is presented. The C-SSR will be used in this study only for the purpose of safety monitoring by measuring the incidence of different types of suicidality categories during treatment. C-SSRS assessment will be based upon a clinician's interpretation of the participant's responses to the C-SSRS questions, not by a numbered scale. Suicidal ideation and/or behaviors identified on the C-SSRS may not be considered an adverse event, based on the investigator's judgment. Participants who report at least one occurrence of suicidal behavior or suicidal ideation will be counted as having experienced suicidality. Suicidal behavior includes suicide attempt, aborted attempt, interrupted attempt, or preparatory behavior. Suicidal ideation include a wish to die or active suicidal thought with or without method, intent or plan.
| Participants | MK-1942 8 mg | MK-1942 15 mg | MK-1942 30 mg | MK-1942 50 mg | Placebo AD |
|---|---|---|---|---|---|
| Number of Participants Who Reported Suicidal Ideation and/or Behavior on Study Based on Responses to the Columbia Suicide Severity Rating Scale (C-SSRS) | 0 | 0 | 0 | 0 | 0 |
The mean change from baseline in HR is presented. Change in HR was determined the first day of treatment with a new dose of MK-1942. A negative value indicates a decrease in HR relative to baseline, and a positive value indicates an increase.
| beats/min | MK-1942 8 mg | MK-1942 15 mg | MK-1942 30 mg | MK-1942 50 mg | Placebo AD |
|---|---|---|---|---|---|
| Change From Baseline in Heart Rate (HR) | -2.27 ± 1.25 | 2.56 ± 1.65 | 6.14 ± 2.27 | 0.21 ± 2.81 | -4.53 ± 1.06 |
The mean change from baseline in SBP is presented. Change in SBP was determined the first day of treatment with a new dose of MK-1942. Negative values represent a decrease in SBP relative to baseline, and positive values represent an increase.
| mmHg | MK-1942 8 mg | MK-1942 15 mg | MK-1942 30 mg | MK-1942 50 mg | Placebo AD |
|---|---|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) | 2.48 ± 2.08 | -0.15 ± 2.59 | 0.88 ± 2.09 | 1.45 ± 2.19 | 5.93 ± 4.00 |
The mean change from baseline in DBP is presented. Change in DBP was determined the first day of treatment with a new dose of MK-1942. Negative values represent a decrease in DBP relative to baseline, and positive values represent an increase.
| mmHg | MK-1942 8 mg | MK-1942 15 mg | MK-1942 30 mg | MK-1942 50 mg | Placebo AD |
|---|---|---|---|---|---|
| Mean Change From Baseline in Diastolic Blood Pressure (DBP) | -0.95 ± 0.93 | 0.56 ± 2.01 | 1.17 ± 1.51 | 0.10 ± 1.39 | -1.73 ± 3.36 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with abnormal chemistry-related AEs is reported.
| Participants | MK-1942 8 mg | MK-1942 15 mg | MK-1942 30 mg | MK-1942 50 mg | Placebo AD |
|---|---|---|---|---|---|
| Number of Participants With Abnormal Clinical Chemistry Test Results Reported as Adverse Events | 1 | 0 | 0 | 1 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with abnormal hematology-related AEs is reported.
| Participants | MK-1942 8 mg | MK-1942 15 mg | MK-1942 30 mg | MK-1942 50 mg | Placebo AD |
|---|---|---|---|---|---|
| Number of Participants With Abnormal Clinical Hematology Test Results Reported as Adverse Events | 0 | 1 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with an abnormal urinalysis results AE is reported.
| Participants | MK-1942 8 mg | MK-1942 15 mg | MK-1942 30 mg | MK-1942 50 mg | Placebo AD |
|---|---|---|---|---|---|
| Number of Participants With Abnormal Urinalysis Results Reported as Adverse Events | 10 | 0 | 0 | 0 | 0 |
AUC0-12 is reported for the first day of treatment of each MK-1942 dose.
| hr*nmol/L | MK-1942 8 mg + Donepezil AD | MK-1942 15 mg + Donepezil AD | MK-1942 30 mg + Donepezil AD | MK-1942 50 mg + Donepezil AD |
|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve (AUC) From Dosing to 12 Hours Postdose (AUC0-12) of MK-1942 | 1760 (1390 to 2240) | 3580 (2860 to 4490) | 6650 (5330 to 8280) | 11600 (9110 to 14700) |
AUC0-24 is reported for the first day of treatment of each MK-1942 dose. Due to twice daily dosing, AUC0-24 was calculated as "AUC0-24 = AUC0-12 x 2".
| hr*nmol/L | MK-1942 8 mg + Donepezil AD | MK-1942 15 mg + Donepezil AD | MK-1942 30 mg + Donepezil AD | MK-1942 50 mg + Donepezil AD |
|---|---|---|---|---|
| AUC From Dosing to 24 Hours Postdose (AUC0-24) of MK-1942 | 3530 (2790 to 4470) | 7160 (5710 to 8970) | 13330 (10700 to 16600) | 23200 (18200 to 29500) |
Cmax is reported for the first day of treatment of each MK-1942 dose.
| nmol/L | MK-1942 8 mg + Donepezil AD | MK-1942 15 mg + Donepezil AD | MK-1942 30 mg + Donepezil AD | MK-1942 50 mg + Donepezil AD |
|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of MK-1942 | 239 (184 to 310) | 477 (371 to 613) | 876 (731 to 1050) | 1360 (1080 to 1720) |
Ctrough is reported for the first day of treatment of each MK-1942 dose. Data from healthy elderly participants used for statistical analyses are unpublished findings from study MK-1942-004.
| nmol/L | MK-1942 8 mg + Donepezil AD | MK-1942 15 mg + Donepezil AD | MK-1942 30 mg + Donepezil AD | MK-1942 50 mg + Donepezil AD |
|---|---|---|---|---|
| Trough Plasma Concentration (Ctrough) of MK-1942 | 101 (79.7 to 127) | 228 (188 to 277) | 386 (282 to 527) | 693 (528 to 910) |
Tmax is reported for the first day of treatment of each MK-1942 dose.
| Hours | MK-1942 8 mg + Donepezil AD | MK-1942 15 mg + Donepezil AD | MK-1942 30 mg + Donepezil AD | MK-1942 50 mg + Donepezil AD |
|---|---|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of MK-1942 | 1.97 (0.93 to 3.00) | 1.98 (0.43 to 3.00) | 2.00 (1.00 to 5.95) | 2.00 (1.93 to 3.08) |
t½ is reported for MK-1942 50 mg.
| Hours | MK-1942 50 mg + Donepezil AD |
|---|---|
| Apparent Terminal Plasma Half-Life (t½) of MK-1942 | 26.7 ± 27.7 |
CLss/F is reported for MK-1942 50 mg.
| L/h | MK-1942 50 mg + Donepezil AD |
|---|---|
| Apparent Clearance at Steady-state (CLss/F) of MK-1942 | 11.7 ± 45.5 |
Vzss/F is reported for MK-1942 50 mg.
| Liters | MK-1942 50 mg + Donepezil AD |
|---|---|
| Apparent Volume of Distribution at Steady State (Vzss/F) of MK-1942 | 449 ± 41.1 |
AUC0-24 is reported for donepezil 10 mg alone (Day -1) or with MK-1942 50 mg (Day 28). Due to twice daily dosing, AUC0-24 was calculated as "AUC0-12 x 2".
| hr*ng/mL | Donepezil Day -1 | Donepezil Day 28 |
|---|---|---|
| AUC0-24 of Donepezil | 606 ± 66.4 | 919 ± 44.4 |
Cmax is reported for donepezil 10 mg alone (Day -1) or with MK-1942 50 mg (Day 28).
| ng/mL | Donepezil Day -1 | Donepezil Day 28 |
|---|---|---|
| Cmax of Donepezil | 37.9 ± 56.4 | 53.3 ± 42.2 |
Ctrough is reported for donepezil 10 mg alone (Day -1) or with MK-1942 50 mg (Day 28).
| ng/mL | Donepezil Day -1 | Donepezil Day 28 |
|---|---|---|
| Ctrough of Donepezil | 20.1 ± 72.7 | 31.8 ± 52.5 |
Tmax is reported for donepezil 10 mg alone (Day -1) or with MK-1942 50 mg (Day 28).
| Hours | Donepezil Day -1 | Donepezil Day 28 |
|---|---|---|
| Tmax of Donepezil | 2.05 (0.00 to 4.00) | 2.03 (1.00 to 3.95) |
Collected over Up to 42 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-1942 8 mg BID 7 Days | 0/22 (0%) | 0/22 (0%) | 13/22 (59.1%) |
| MK-1942 15 mg BID 7 Days | 0/19 (0%) | 0/19 (0%) | 4/19 (21.1%) |
| MK-1942 30 mg Bid 7D | 0/15 (0%) | 0/15 (0%) | 4/15 (26.7%) |
| MK-1942 50 mg BID & Days | 0/15 (0%) | 0/15 (0%) | 5/15 (33.3%) |
| MK-1942 Total | 0/22 (0%) | 0/22 (0%) | 18/22 (81.8%) |
| Placebo Bid | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Event | MK-1942 8 mg BID 7 Days | MK-1942 15 mg BID 7 Days | MK-1942 30 mg Bid 7D | MK-1942 50 mg BID & Days | MK-1942 Total | Placebo Bid |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 5/22 | 1/19 | 0/15 | 2/15 | 7/22 | 2/5 |
| HeadacheNervous system disorders | 1/22 | 0/19 | 0/15 | 0/15 | 1/22 | 2/5 |
| DizzinessNervous system disorders | 3/22 | 0/19 | 2/15 | 0/15 | 5/22 | 1/5 |
| Scleral hyperaemiaEye disorders | 0/22 | 0/19 | 0/15 | 0/15 | 0/22 | 1/5 |
| Vision blurredEye disorders | 1/22 | 0/19 | 0/15 | 0/15 | 1/22 | 1/5 |
| Gait disturbanceGeneral disorders | 0/22 | 0/19 | 0/15 | 0/15 | 0/22 | 1/5 |
| Oedema peripheralGeneral disorders | 0/22 | 0/19 | 0/15 | 0/15 | 0/22 | 1/5 |
| Vessel puncture site bruiseGeneral disorders | 0/22 | 0/19 | 0/15 | 0/15 | 0/22 | 1/5 |
| Upper respiratory tract infectionInfections and infestations | 0/22 | 0/19 | 0/15 | 0/15 | 0/22 | 1/5 |
| Electrocardiogram T wave biphasicInvestigations | 0/22 | 0/19 | 0/15 | 0/15 | 0/22 | 1/5 |
| Age, Continuous(years) | MK-1942 AD | Placebo + Donepezil AD | Total |
|---|---|---|---|
| Mean | 69.1 ± 5.5 | 69.4 ± 2.6 | 69.2 ± 5.0 |
| Sex: Female, Male(Participants) | MK-1942 AD | Placebo + Donepezil AD | Total |
|---|---|---|---|
| Female | 10 | 2 | 12 |
| Male | 12 | 3 | 15 |
| Ethnicity (NIH/OMB)(Participants) | MK-1942 AD | Placebo + Donepezil AD | Total |
|---|---|---|---|
| Hispanic or Latino | 19 | 4 | 23 |
| Not Hispanic or Latino | 2 | 1 | 3 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | MK-1942 AD | Placebo + Donepezil AD | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 0 | 7 |
| White | 15 | 5 | 20 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2021 to primary completion in May 2022, 15 months.
Results were first posted in Aug 2024, 2 years 2 months after primary completion.
Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 15 months is above that.
Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: MK-1942 · Donepezil